
Biotech Breakout? How a 2-Week Depression Pill Could Trigger a Market Repricing
As biotech valuations shift and investor focus pivots to fast-acting mental health treatments, a powerful therapeutic quietly sits at the center of a stalled commercial story. Zurzuvae (zuranolone), a two-week oral antidepressant, has the potential to …